jm970364a_si_001.pdf (300.75 kB)

Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701):  A Uroselective α1A Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia

Download (300.75 kB)
journal contribution
posted on 26.09.1997, 00:00 by Michael D. Meyer, Robert J. Altenbach, Fatima Z. Basha, William A. Carroll, Irene Drizin, Steven W. Elmore, Paul P. Ehrlich, Suzanne A. Lebold, Karin Tietje, Kevin B. Sippy, Michael D. Wendt, Daniel J. Plata, Fred Plagge, Steven A. Buckner, Michael E. Brune, Arthur A. Hancock, James F. Kerwin
Synthesis and Pharmacological Characterization of 3-[2-((3aR,9bR)-cis-6-Methoxy- 2,3,3a,4,5,9b-hexahydro-1H- benz[e]isoindol-2-yl)ethyl]pyrido[3‘,4‘:4,5]thieno[3,2-d]pyrimidine- 2,4(1H,3H)-dione (A-131701):  A Uroselective α1A Adrenoceptor Antagonist for the Symptomatic Treatment of Benign Prostatic Hyperplasia

History